Gatifloxacin-based treatment outcome for 62 patients with QRDR mutants stratified by resistance profile to accompanying drugs per isolate; only one pre-MDR-treatment isolate per patient included
| Resistance profile to accompanying drugs (KAN/INH/EMB/ETH/PZA/CFZ) . | Number of isolates yielding a valid DST result for the accompanying drugs . | Cured . | Failed . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| None or single drug | 9 | 3 | 33.3 | 6 | 66.7 |
| susceptible | 4 | 0 | 4 | ||
| ETH | 1 | 1 | 0 | ||
| INHa | 4 | 2 | 2 | ||
| Two drugs | 25 | 13 | 52.0 | 12 | 48.0 |
| INH/EMBb | 14 | 6 | 8 | ||
| INH/PZA | 9 | 5 | 4 | ||
| INH/CFZc | 2 | 2 | 0 | ||
| Subtotal for none, single drug or two drugs | 34 | 16 | 47.1 | 18 | 52.9 |
| Three drugs | 21 | 10 | 47.6 | 11 | 52.4 |
| INH/EMB/ETH | 18 | 9 | 9 | ||
| INH/EMB/PZAc | 2 | 0 | 2 | ||
| INH/PZA/CFZ | 1 | 1 | 0 | ||
| Four drugs | 7 | 5 | 71.4 | 2 | 28.6 |
| INH/EMB/ETH/PZA | 4 | 3 | 1 | ||
| INH/EMB/PZA/CFZ | 3 | 2 | 1 | ||
| Subtotal for three drugs or four drugs | 28 | 15 | 53.6 | 13 | 46.4 |
| Total | 62 | 31 | 50.0 | 31 | 50.0 |
| Resistance profile to accompanying drugs (KAN/INH/EMB/ETH/PZA/CFZ) . | Number of isolates yielding a valid DST result for the accompanying drugs . | Cured . | Failed . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| None or single drug | 9 | 3 | 33.3 | 6 | 66.7 |
| susceptible | 4 | 0 | 4 | ||
| ETH | 1 | 1 | 0 | ||
| INHa | 4 | 2 | 2 | ||
| Two drugs | 25 | 13 | 52.0 | 12 | 48.0 |
| INH/EMBb | 14 | 6 | 8 | ||
| INH/PZA | 9 | 5 | 4 | ||
| INH/CFZc | 2 | 2 | 0 | ||
| Subtotal for none, single drug or two drugs | 34 | 16 | 47.1 | 18 | 52.9 |
| Three drugs | 21 | 10 | 47.6 | 11 | 52.4 |
| INH/EMB/ETH | 18 | 9 | 9 | ||
| INH/EMB/PZAc | 2 | 0 | 2 | ||
| INH/PZA/CFZ | 1 | 1 | 0 | ||
| Four drugs | 7 | 5 | 71.4 | 2 | 28.6 |
| INH/EMB/ETH/PZA | 4 | 3 | 1 | ||
| INH/EMB/PZA/CFZ | 3 | 2 | 1 | ||
| Subtotal for three drugs or four drugs | 28 | 15 | 53.6 | 13 | 46.4 |
| Total | 62 | 31 | 50.0 | 31 | 50.0 |
INH, isoniazid at 1 mg/L; EMB, ethambutol; ETH, ethionamide; KAN, kanamycin; PZA, pyrazinamide; CFZ, clofazimine.
Clofazimine and pyrazinamide were tested genotypically by sequencing Rv0678 and pncA genes, respectively.
aOne failure patient lacked clofazimine data.
bTwo failure and two cured patients lacked pyrazinamide or clofazimine data.
cOne cured patient lacked ethionamide data.
Gatifloxacin-based treatment outcome for 62 patients with QRDR mutants stratified by resistance profile to accompanying drugs per isolate; only one pre-MDR-treatment isolate per patient included
| Resistance profile to accompanying drugs (KAN/INH/EMB/ETH/PZA/CFZ) . | Number of isolates yielding a valid DST result for the accompanying drugs . | Cured . | Failed . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| None or single drug | 9 | 3 | 33.3 | 6 | 66.7 |
| susceptible | 4 | 0 | 4 | ||
| ETH | 1 | 1 | 0 | ||
| INHa | 4 | 2 | 2 | ||
| Two drugs | 25 | 13 | 52.0 | 12 | 48.0 |
| INH/EMBb | 14 | 6 | 8 | ||
| INH/PZA | 9 | 5 | 4 | ||
| INH/CFZc | 2 | 2 | 0 | ||
| Subtotal for none, single drug or two drugs | 34 | 16 | 47.1 | 18 | 52.9 |
| Three drugs | 21 | 10 | 47.6 | 11 | 52.4 |
| INH/EMB/ETH | 18 | 9 | 9 | ||
| INH/EMB/PZAc | 2 | 0 | 2 | ||
| INH/PZA/CFZ | 1 | 1 | 0 | ||
| Four drugs | 7 | 5 | 71.4 | 2 | 28.6 |
| INH/EMB/ETH/PZA | 4 | 3 | 1 | ||
| INH/EMB/PZA/CFZ | 3 | 2 | 1 | ||
| Subtotal for three drugs or four drugs | 28 | 15 | 53.6 | 13 | 46.4 |
| Total | 62 | 31 | 50.0 | 31 | 50.0 |
| Resistance profile to accompanying drugs (KAN/INH/EMB/ETH/PZA/CFZ) . | Number of isolates yielding a valid DST result for the accompanying drugs . | Cured . | Failed . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| None or single drug | 9 | 3 | 33.3 | 6 | 66.7 |
| susceptible | 4 | 0 | 4 | ||
| ETH | 1 | 1 | 0 | ||
| INHa | 4 | 2 | 2 | ||
| Two drugs | 25 | 13 | 52.0 | 12 | 48.0 |
| INH/EMBb | 14 | 6 | 8 | ||
| INH/PZA | 9 | 5 | 4 | ||
| INH/CFZc | 2 | 2 | 0 | ||
| Subtotal for none, single drug or two drugs | 34 | 16 | 47.1 | 18 | 52.9 |
| Three drugs | 21 | 10 | 47.6 | 11 | 52.4 |
| INH/EMB/ETH | 18 | 9 | 9 | ||
| INH/EMB/PZAc | 2 | 0 | 2 | ||
| INH/PZA/CFZ | 1 | 1 | 0 | ||
| Four drugs | 7 | 5 | 71.4 | 2 | 28.6 |
| INH/EMB/ETH/PZA | 4 | 3 | 1 | ||
| INH/EMB/PZA/CFZ | 3 | 2 | 1 | ||
| Subtotal for three drugs or four drugs | 28 | 15 | 53.6 | 13 | 46.4 |
| Total | 62 | 31 | 50.0 | 31 | 50.0 |
INH, isoniazid at 1 mg/L; EMB, ethambutol; ETH, ethionamide; KAN, kanamycin; PZA, pyrazinamide; CFZ, clofazimine.
Clofazimine and pyrazinamide were tested genotypically by sequencing Rv0678 and pncA genes, respectively.
aOne failure patient lacked clofazimine data.
bTwo failure and two cured patients lacked pyrazinamide or clofazimine data.
cOne cured patient lacked ethionamide data.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
